<DOC>
	<DOCNO>NCT00510029</DOCNO>
	<brief_summary>The study ass safety , tolerability pharmacokinetics single intravenous ( IV ) dose GAP-134 healthy subject . GAP-134 administered 24-hour infusion .</brief_summary>
	<brief_title>Single Ascending Dose Study Safety , Tolerability , Pharmacokinetics GAP-134 Administered Intravenously</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Generally healthy men woman nonchildbearing potential ( WONCBP ) , age 18 50 year . Body Mass Index ( BMI ) range 18 30 kg/m2 . Blood serum creatinine level less equal upper limit normal . Exclusion Criteria Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . Any history clinically important cardiac arrhythmias familial history long QT syndrome unexpected cardiac death . History drug alcohol abuse , positive HIV , HCV , and/or HBs Ag test , clinically important deviation normal limit physical examination , vital sign , 12lead ECGs , clinical laboratory test result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>